Can Medical Device Test Reports for Brazilian Registration Be Reused?

Answer: For the question of whether medical device test reports for Brazilian registration can be reused, companies should first confirm the target country, product risk classification, applicable regulatory pathway, and existing documentation base, then assess technical documentation, quality management system, labels and instructions for use, local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends conducting a documentation gap assessment before formal submission to avoid prolonging project timelines due to unclear classification, documentation, or authorization arrangements.

Published: 2026-07-11 22:27 | Updated: 2026-07-11 22:27

This article addresses international medical device registration, documentation preparation, compliance pathways, and post-market maintenance, outlining the questions companies should prioritize in actual projects.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documentation and Evidence
• Common Mistakes
• Company Preparation Checklist
• AIMEILI Perspective
• Common Follow-up Questions
• Continue Reading
• Applicable Boundaries

Key Summary

Regarding whether medical device test reports for Brazilian registration can be reused, companies should first confirm the target country, product risk classification, applicable regulatory pathway, and existing documentation base, then assess technical documentation, quality management system, labels and IFU, local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends a documentation gap assessment before formal submission to avoid prolonging project timelines due to unclear classification, documentation, or authorization arrangements.

For Chinese medical device companies, a more reliable approach is to first perform product classification and a documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documents can be reused. Brazilian registration typically affects technical documentation, authorized representative, importer cooperation, label language, quality system certification, and subsequent change maintenance simultaneously. If the project is advanced only on the basis of 'which documents to submit,' deficiencies or rework can easily arise in model coverage, evidence chain consistency, label claims, and certificate control. AIMEILI recommends that companies incorporate this question into a unified GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets, rather than preparing documents from scratch for each country on an ad hoc basis.

Applicable Scenarios and Core Questions

Companies searching for 'whether medical device test reports for Brazilian registration can be reused' are usually not seeking a conceptual explanation. They want to determine whether existing documentation can support a Brazilian submission, whether a local agent or authorized representative is needed, why timelines may be prolonged, and which issues could affect market launch plans. Behind this question are often product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America simultaneously, answering the process for one country alone is not enough. A more valuable approach is to first make the core technical file, quality system certification, performance verification, clinical evidence, and labels/IFU into reusable versions, then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, method of body contact, duration of use, whether it is sterile, whether it is active, and whether it contains software or IVD attributes, then determine the risk class and submission pathway. Once the pathway is wrong, subsequent translation, notarization, authorization, testing, and supplementary documentation will all deviate from the correct direction.

For Brazilian projects, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely only in commercial contracts, they can easily affect market control later.

Documentation and Evidence

Common documents include product description, model/specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system certification, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labels and IFU, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documentation.

The key to document quality is not quantity but consistency. IFU claims, model coverage in test reports, applicable scope of clinical evidence, risk management conclusions, label warnings, and registration application form information must support each other. Regulatory agencies focus on whether the product is safe, effective, and traceable for the intended use, not on whether the company uploaded many documents.

Common Mistakes

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Directly translating domestic NMPA documents and submitting them without rearranging evidence according to the Brazilian pathway.
• Too many models/specifications, but insufficient coverage in test reports, clinical evidence, or labels.
• Selecting a local agent only on the basis of sales cooperation, without clarifying regulatory responsibility, certificate control, and post-market maintenance obligations.
• Inconsistency between labels, IFU, promotional materials, and registration claims, leading to deficiencies or post-market compliance risks.
• Failing to plan multi-country document reuse in advance, resulting in repeated preparation for each country and multiplied costs and timelines.

Company Preparation Checklist

Before starting the project, companies are advised to use an internal checklist to confirm the documentation base, avoiding the discovery of critical evidence gaps after submission.

• Organize the target product list, model/specification matrix, and intended use description.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English IFU.
• Confirm the responsibilities, fees, certificate control, and exit mechanism of the local agent or authorized representative.
• Establish a target-country gap assessment table, specifying what needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI Perspective

AIMEILI recommends that companies not view Brazilian registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first, then converting it according to each country's requirements, is usually faster, more stable, and more conducive to subsequent changes and renewals than preparing documents on an ad hoc basis for each country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, regulatory responsibility boundaries of local partners. If these three items are unclear, even if documents appear abundant, the project may still experience repeated issues during deficiency responses, agent communication, and post-market maintenance.

Common Follow-up Questions

Can domestic documents be directly used for Brazilian registration?

Domestic documents can serve as a basis, but usually cannot be submitted as-is. Companies need to adjust the document structure, language, labels, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in registration communication, changes, renewals, and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project ledger to manage the product list, model/specifications, registration pathway, document owners, translation status, testing status, local agent communication records, and expected submission time in one table. This helps identify document gaps in a timely manner and allows management to judge whether the project will affect market launch plans.

For companies with existing registrations in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to country requirements. In particular, labels/IFU, clinical evaluation, risk management, performance verification, and quality system certificates must maintain consistent versions.

• Confirm target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify local agent and certificate control.
• Track translation, notarization, testing, and deficiency status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documents are not isolated certificates. Regulatory agencies typically examine whether the manufacturer name, manufacturing address, product scope, certificate validity, applicable standards, and technical file are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the manufacturing address, model/specifications, IFU version, and test reports are inconsistent, even if a large number of documents have been prepared, supplementary explanations may be required.

Companies should establish an evidence consistency checklist before submission, mapping product name, model/specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label/IFU version, and quality system certificate item by item. This action may seem basic, but it can significantly reduce the probability of deficiencies, especially for projects submitted simultaneously to multiple GHWP member states or for multiple product families.

Localization Conversion and Agent Responsibilities

Brazilian registration projects typically involve local agent, authorized representative, importer, or registration holder arrangements. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFU, and authorization documents also cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documents, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance. If a manufacturing address change, model expansion, IFU update, or agent replacement occurs later, the certificate can easily become disconnected from actual market sales.

AIMEILI recommends that companies manage this issue as part of an annual international registration plan: first clarify target market priorities, then establish a reusable document package and country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value of this approach is not only improving registration efficiency in a single country, but more importantly enabling companies to develop replicable overseas compliance capabilities and reduce the cost of starting from scratch each time they enter a new market.

Continue Reading

Previous: How to Prepare Clinical Evaluation Documents for Brazilian Medical Device Registration?

Next: How to Use ISO 13485 Certificates for Brazilian Medical Device Registration?

Recommended Reading:

• What Are the Risk Management Document Requirements for Philippine Medical Device Registration?
• How to Prepare Performance Verification Documents for Philippine Medical Device Registration?
• What to Do When Quality System Certifications Are Inconsistent for Philippine Medical Device Registration?
• How to Prepare Registration Documents for Singapore Medical Device Registration?
• How to Determine Product Classification for Singapore Medical Device Registration?
• How to Organize Technical Files for Singapore Medical Device Registration?

Back to FAQ Center | News | Contact AIMEILI

Content Review and Applicable Boundaries

Content Author: AIMEILI Regulatory Editorial Team

Professional Review: AIMEILI Medical Device International Registration Project Team

Source Principles: Prioritize official regulatory agencies, international organizations, standards organizations, and publicly available regulatory documents; industry media and project experience are used only as auxiliary judgment.

Applicable Boundaries: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of target country regulatory agencies, testing conclusions, or legal opinions.